Vimarsana
Biggest News Aggregation in the World

Selecta Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Selecta Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Selecta Bioscience Today - Breaking & Trending Today

Head to Head Review: Takeda Pharmaceutical (NYSE:TAK) vs. Nurix Therapeutics (NASDAQ:NRIX) - Vimarsana News

Head to Head Review: Takeda Pharmaceutical (NYSE:TAK) vs. Nurix Therapeutics (NASDAQ:NRIX)

Takeda Pharmaceutical (NYSE:TAK – Get Free Report) and Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk. Volatility and Risk Takeda Pharmaceutical has a beta […]

Source: wkrb13.com
Analyzing WuXi Biologics (Cayman) (OTCMKTS:WXXWY) and Selecta Biosciences (NASDAQ:SELB) - Vimarsana News

Analyzing WuXi Biologics (Cayman) (OTCMKTS:WXXWY) and Selecta Biosciences (NASDAQ:SELB)

WuXi Biologics (Cayman) (OTCMKTS:WXXWY – Get Free Report) and Selecta Biosciences (NASDAQ:SELB – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends. Analyst Recommendations This is a summary of […]

Selecta Biosciences, Inc.'s (NASDAQ:SELB) largest shareholders are individual investors with 35% ownership, institutions own 26% - Vimarsana News

Selecta Biosciences, Inc.'s (NASDAQ:SELB) largest shareholders are individual investors with 35% ownership, institutions own 26%

Key Insights Selecta Biosciences' significant individual investors ownership suggests that the key decisions are...

Source: yahoo.com
SVB Leerink Analysts Increase Earnings Estimates for Selecta Biosciences, Inc. (NASDAQ:SELB) - Vimarsana News

SVB Leerink Analysts Increase Earnings Estimates for Selecta Biosciences, Inc. (NASDAQ:SELB)

Selecta Biosciences, Inc. (NASDAQ:SELB – Get Rating) – Research analysts at SVB Leerink upped their Q1 2023 earnings per share (EPS) estimates for shares of Selecta Biosciences in a report released on Tuesday, March 21st. SVB Leerink analyst J. Schwartz now expects that the company will post earnings of ($0.01) per share for the quarter, […]

Zacks: Analysts Expect Selecta Biosciences, Inc. (NASDAQ:SELB) Will Post Quarterly Sales of $19.07 Million - Vimarsana News

Zacks: Analysts Expect Selecta Biosciences, Inc. (NASDAQ:SELB) Will Post Quarterly Sales of $19.07 Million

Wall Street analysts forecast that Selecta Biosciences, Inc. (NASDAQ:SELB – Get Rating) will report $19.07 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Selecta Biosciences’ earnings. The highest sales estimate is $23.15 million and the lowest is $15.00 million. Selecta Biosciences reported sales of […]